Our findings provide evidence that TGQZD can exert therapeutic effects on NAFLD and reduces the accumulation of lipids in the liver by regulating the level of lipoproteins; improving hepatic function, inhibiting FFA metabolism, and promoting CGI-58 expression to suppress the activation of the ROS-dependent NLRP3 inflammasome pathway, which ultimately reduces liver inflammatory injury. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.